Kim Kamdar

Kim earned her BA from Northwestern University and her PhD from Emory University.

Kim joined Domain Associates in 2005 and became a partner in 2011. With a background in small molecule drug discovery, Kim has been involved in cutting-edge therapeutic startups and has been a major part of identifying companies with promising molecular and companion diagnostics to support personalized medicine. 

​

Kim's present board memberships include Epic Sciences, Neothetics, Obalon Therapeutics, ROX Medical, Sera Prognostics, Syndax Pharmaceuticals and Tragara Pharmaceuticals. She was also involved with Ariosa Diagnostics (sold to Roche), Corthera (sold to Novartis), and BiPar Sciences (sold to sanofi-aventis). 

​

Prior to Domain, Kim was a Kauffman Fellow with MPM Capital. Prior to joining MPM, she was a research director at Novartis, where she built and led a research team that focused on the biology, genetics, and genomics of model organisms to uncover small molecules that modulated signaling pathway networks. Kim is a founder of Aryzun Pharmaceuticals, a biotech company utilizing protein-protein interaction mapping for small molecule discovery with an initial focus on anti-infectives and oncology. 

​

Kim is the author of ten papers as well as the inventor on seven patents.

Kim served her fellowship as a member of Class 8 under mentor Nick Galakatos at MPM Capital in Boston, MA.